← Back to Search
Treatment Of Newly Diagnosed Glioblastoma In The Elderly: A Network Meta-analysis.
C. Hanna, T. Lawrie, E. Rogozińska, Ashleigh Kernohan, S. Jefferies, Helen J Bulbeck, U. Ali, T. Robinson, R. Grant
Published 2020 · Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND A glioblastoma is a fatal type of brain tumour for which the standard of care is maximum surgical resection followed by chemoradiotherapy, when possible. Age is an important consideration in this disease, as older age is associated with shorter survival and a higher risk of treatment-related toxicity. OBJECTIVES To determine the most effective and best-tolerated approaches for the treatment of elderly people with newly diagnosed glioblastoma. To summarise current evidence for the incremental resource use, utilities, costs and cost-effectiveness associated with these approaches. SEARCH METHODS We searched electronic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase to 3 April 2019, and the NHS Economic Evaluation Database (EED) up to database closure. We handsearched clinical trial registries and selected neuro-oncology society conference proceedings from the past five years. SELECTION CRITERIA Randomised trials (RCTs) of treatments for glioblastoma in elderly people. We defined 'elderly' as 70+ years but included studies defining 'elderly' as over 65+ years if so reported. DATA COLLECTION AND ANALYSIS We used standard Cochrane methods for study selection and data extraction. Where sufficient data were available, treatment options were compared in a network meta-analysis (NMA) using Stata software (version 15.1). For outcomes with insufficient data for NMA, pairwise meta-analysis were conducted in RevMan. The GRADE approach was used to grade the evidence. MAIN RESULTS We included 12 RCTs involving approximately 1818 participants. Six were conducted exclusively among elderly people (either defined as 65 years or older or 70 years or older) with newly diagnosed glioblastoma, the other six reported data for an elderly subgroup among a broader age range of participants. Most participants were capable of self-care. Study quality was commonly undermined by lack of outcome assessor blinding and attrition. NMA was only possible for overall survival; other analyses were pair-wise meta-analyses or narrative syntheses. Seven trials contributed to the NMA for overall survival, with interventions including supportive care only (one trial arm); hypofractionated radiotherapy (RT40; four trial arms); standard radiotherapy (RT60; five trial arms); temozolomide (TMZ; three trial arms); chemoradiotherapy (CRT; three trial arms); bevacizumab with chemoradiotherapy (BEV_CRT; one trial arm); and bevacizumab with radiotherapy (BEV_RT). Compared with supportive care only, NMA evidence suggested that all treatments apart from BEV_RT prolonged survival to some extent. Overall survival High-certainty evidence shows that CRT prolongs overall survival (OS) compared with RT40 (hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.56 to 0.80) and low-certainty evidence suggests that CRT may prolong overall survival compared with TMZ (TMZ versus CRT: HR 1.42, 95% CI 1.01 to 1.98). Low-certainty evidence also suggests that adding BEV to CRT may make little or no difference (BEV_CRT versus CRT: HR 0.83, 95% CrI 0.48 to 1.44). We could not compare the survival effects of CRT with different radiotherapy fractionation schedules (60 Gy/30 fractions and 40 Gy/15 fractions) due to a lack of data. When treatments were ranked according to their effects on OS, CRT ranked higher than TMZ, RT and supportive care only, with the latter ranked last. BEV plus RT was the only treatment for which there was no clear benefit in OS over supportive care only. One trial comparing tumour treating fields (TTF) plus adjuvant chemotherapy (TTF_AC) with adjuvant chemotherapy alone could not be included in the NMA as participants were randomised after receiving concomitant chemoradiotherapy, not before. Findings from the trial suggest that the intervention probably improves overall survival in this selected patient population. We were unable to perform NMA for other outcomes due to insufficient data. Pairwise analyses were conducted for the following. Quality of life Moderate-certainty narrative evidence suggests that overall, there may be little difference in QoL between TMZ and RT, except for discomfort from communication deficits, which are probably more common with RT (1 study, 306 participants, P = 0.002). Data on QoL for other comparisons were sparse, partly due to high dropout rates, and the certainty of the evidence tended to be low or very low. Progression-free survival High-certainty evidence shows that CRT increases time to disease progression compared with RT40 (HR 0.50, 95% CI 0.41 to 0.61); moderate-certainty evidence suggests that RT60 probably increases time to disease progression compared with supportive care only (HR 0.28, 95% CI 0.17 to 0.46), and that BEV_RT probably increases time to disease progression compared with RT40 alone (HR 0.46, 95% CI 0.27 to 0.78). Evidence for other treatment comparisons was of low- or very low-certainty. Severe adverse events Moderate-certainty evidence suggests that TMZ probably increases the risk of grade 3+ thromboembolic events compared with RT60 (risk ratio (RR) 2.74, 95% CI 1.26 to 5.94; participants = 373; studies = 1) and also the risk of grade 3+ neutropenia, lymphopenia, and thrombocytopenia. Moderate-certainty evidence also suggests that CRT probably increases the risk of grade 3+ neutropenia, leucopenia and thrombocytopenia compared with hypofractionated RT alone. Adding BEV to CRT probably increases the risk of thromboembolism (RR 16.63, 95% CI 1.00 to 275.42; moderate-certainty evidence). Economic evidence There is a paucity of economic evidence regarding the management of newly diagnosed glioblastoma in the elderly. Only one economic evaluation on two short course radiotherapy regimen (25 Gy versus 40 Gy) was identified and its findings were considered unreliable. AUTHORS' CONCLUSIONS For elderly people with glioblastoma who are self-caring, evidence suggests that CRT prolongs survival compared with RT and may prolong overall survival compared with TMZ alone. For those undergoing RT or TMZ therapy, there is probably little difference in QoL overall. Systemic anti-cancer treatments TMZ and BEV carry a higher risk of severe haematological and thromboembolic events and CRT is probably associated with a higher risk of these events. Current evidence provides little justification for using BEV in elderly patients outside a clinical trial setting. Whilst the novel TTF device appears promising, evidence on QoL and tolerability is needed in an elderly population. QoL and economic assessments of CRT versus TMZ and RT are needed. More high-quality economic evaluations are needed, in which a broader scope of costs (both direct and indirect) and outcomes should be included.
This paper references
Postoperative chemoradiotherapy for elderly patients with glioblastoma: worsening frailty or increasing survival?
V. Pinzi (2017)
Measuring inconsistency in meta-analyses
J. Higgins (2003)
Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation.
R. Sharma (2003)
Efficacy of ‘8-drugs-in-one-day’ combination in treatment of recurrent GBM patients
A. Boiardi (2004)
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★
V. Levin (2005)
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
C. Balaña (2016)
RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
M. Khasraw (2018)
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
G. Minniti (2012)
Fractionation study in the treatment of glioblastoma multiforme.
W. J. Simpson (1976)
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
M. Weller (2003)
Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
M. Boisen (2018)
A randomized trial of accelerated hyperfractionated radiation therapy and bis‐chlorethyl nitrosourea for malignant glioma. A preliminary report of radiation therapy oncology group 83–02
W. Curran (1992)
Response criteria for phase II studies of supratentorial malignant glioma.
D. Macdonald (1990)
Abstract CT007: Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multi-center, phase III trial
R. Stupp (2017)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
W. Wick (2012)
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
B. Chauffert (2014)
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
M. Taphoorn (2015)
Short-course Radiotherapy in Elderly and Frail Patients with Glioblastoma Multiforme. A Phase II Study
B. Jeremic (2004)
Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients
D. Yang (2018)
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
S. Mallick (2018)
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
T. Wakabayashi (2018)
Management of Elderly Patients with Glioblastoma after CE.6
Sunit Das (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
D. N. Louis (2016)
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study
C. Chang (1983)
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
M. Cohen (2005)
Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms
F. Woodcock (2018)
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
K. Field (2015)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
R. Stupp (2005)
Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
S. Grossman (2003)
Supratentorial Glioblastoma Multiforme: The Role of Surgical Resection Versus Biopsy Among Older Patients
K. Chaichana (2010)
A randomized clinical trial for the treatment of glioblastoma multiforme with the individualized dendritic cell-based cancer immunotherapy AV0113.
T. Felzmann (2014)
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
G. Reyes-Botero (2018)
Effect of surgical, Addison's disease on advanced carcinoma of the breast and prostate
S. Taylor (1953)
Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany
A. Waschke (2018)
Quality of life in patients with glioblastoma multiforme participating in a randomized study of brachytherapy as a boost treatment.
J. Bampoe (2000)
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
U. Herrlinger (2016)
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.
W. Roa (2004)
Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial.
Douglas Guedes de Castro (2017)
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas
J. Hildebrand (1994)
A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas.
F. Imbesi (2006)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Act Investigators (2017)
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Bruno Kovic (2015)
Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
D. Nelson (1988)
Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio
Martha Nowosielski (2018)
Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma
T. Elliott (2004)
Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article.
K. Chaichana (2011)
Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme
A. Sijben (2008)
Improved cost-effectiveness of short-course radiotherapy in elderly and/or frail patients with glioblastoma.
Sunita Ghosh (2018)
Combined-modality hypofractionated radiotherapy for elderly patients with glioblastoma: setting a new standard
B. Vellayappan (2017)
Single versus multiple drug therapy in the combined treatment of malignant gliomas. A multicenter study.
R. Knerich (1990)
Concurrent Chemoradiotherapy with Weekly Paclitaxel in Malignant Cerebral Glioma Treatment
José Paulo Montemor (2008)
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02)
B. Corn (1994)
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
L. Nabors (2015)
Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors
Y. Iwadate (2005)
Randomized Trial for Short-Term Radiation Therapy With Temozolomide in Elderly Patients With Glioblastoma.
David J McCarthy (2017)
Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation
V. Meij (2005)
A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.
N. Bleehen (1981)
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
M. Puhan (2014)
Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers
J. Jansen (2013)
Long-Term Follow-Up of Brachytherapy in Untreated Malignant Glioma
P. Hitchon (1999)
A population-based study of glioblastoma multiforme.
L. Paszat (2001)
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients
A. Ali (2017)
Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial
B. Gliński (2005)
Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria.
S. Evers (2005)
Visualizing Assumptions and Results in Network Meta-analysis: The Network Graphs Package
A. Chaimani (2015)
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02
M. Werner-wasik (1996)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
P. Chinnaiyan (2018)
Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study.
D. Szczepanek (2013)
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
R. Stupp (2002)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
R. Stupp (2015)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
R. Stupp (2014)
Randomized Comparison of Intra-arterial Versus Intravenous Infusion of ACNU for Newly Diagnosed Patients with Glioblastoma
M. Kochi (2004)
Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients
S. Jiang (2017)
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
V. Levin (1979)
Regarding "abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial".
M. Chamberlain (2005)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
R. Stupp (2009)
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
M. Bower (1997)
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
M. Gilbert (2013)
High-grade astrocytoma treated concomitantly with estramustine and radiotherapy
R. Henriksson (2005)
A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma.
C. Phillips (2003)
Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article.
W. Stummer (2011)
Misonidazole and irradiation in the treatment of high-grade astrocytomas: further report of the Vienna Study Group.
B. Stadler (1984)
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
M. Prados (2001)
Development of the summary of findings table for network meta-analysis.
Juan José Yepes-Nuñez (2019)
OS09.8 Randomized placebo-controlled trial of autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Y. Muragaki (2017)
Conceptual and Technical Challenges in Network Meta-analysis
A. Cipriani (2013)
Radioendocrine Therapy of Brain Tumors with the Long Acting Opioid Antagonist Naltrexone in Association with Radiotherapy
P. Lissoni (1993)
A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients
An-An Yin (2013)
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
Maria Teresa Solomón (2012)
Early toxicity predicts long-term survival in high-grade glioma
Y. Lawrence (2011)
Patterns of care in elderly glioblastoma patients
F. Iwamoto (2008)
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
S. B. Green (1983)
Treatment of newly diagnosed glioblastoma in the elderly.
T. Lawrie (2019)
Misonidazole combined with hyperfractionation in the management of malignant glioma.
D. Fulton (1984)
Hospitalizations in elderly glioblastoma patients.
C. Moroney (2017)
Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial.
R. Urtasun (1982)
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
S. Combs (2008)
ACTR-17. EFFECT OF AGE ON OUTCOME IN THE GLARIUS TRIAL
S. Kebir (2016)
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma
J. Zhu (2017)
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
D. S. Kong (2017)
薫雄 原田 (1996)
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs
A. Henaine (2016)
OS07.9 Standard of care temozolomide chemotherapy ± tumor treating fields (TTFields) in newly diagnosed glioblastoma. Final results of the phase III EF-14 clinical trial
R. Stupp (2017)
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
O. Chinot (2014)
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
N. Schäfer (2018)
An Analysis of Radiotherapy Data from the CNS Cancer Consortium's Randomized Prospective Trial Comparing AZQ to BCNU in the Treatment of Patients with Primary Malignant Brain Tumors
E. Halperin (1993)
Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population.
Saurabh Ray (2014)
Treatment of Supratentorial Glioblastoma Multiforme with Radiotherapy and a Combination of BCNU and Tamoxifen: A Phase II Study
M. Napolitano (2004)
Fast neutrons compared with megavoltage x-rays in the treatment of patients with supratentorial glioblastoma: a controlled pilot study.
M. Catterall (1980)
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
W. Shapiro (1992)
Adjuvant nitrosourea therapy for glioblastoma.
R. Brisman (1976)
PD-0519: Short course vs. standard course radiotherapy, in elderly and/or fragile patients with glioblastoma multiforme
L. Kępka (2014)
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
H-G Wirsching (2018)
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
F. Saran (2016)
Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
G. Lanzetta (2003)
Rating the certainty in evidence in the absence of a single estimate of effect
M. Murad (2017)
Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients
J. Socha (2015)
The results of a randomised trial of mixed-schedule (neutron/photon) irradiation in the treatment of supratentorial Grade III and Grade IV astrocytoma.
W. Duncan (1986)
Effects of ACNU and radiotherapy on malignant glioma.
K. Takakura (1986)
Superfractionated radiotherapy in grade III, IV intracranial gliomas.
C. Ludgate (1988)
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
E. Halperin (1996)
Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
C. Solero (1979)
Treatment outcomes in newly diagnosed malignant glioma in elderly patients
Muhammad Dherijha (2018)
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis
Sergey V Roussakow (2017)
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
T. Batchelor (2013)
Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms
B. Doble (2015)
Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis
Sudheer R. Thumma (2012)
Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma
K. Field (2017)
Controlled study of CCNU and radiation therapy in malignant astrocytoma.
T. Reagan (1976)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
R. Stupp (2017)
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Eudocia Q. Lee (2015)
ALA and Photofrin® Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial
M. Eljamel (2007)
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial
C. Schaub (2018)
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
G. Guzauskas (2019)
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
V. Levin (2000)
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
T. Armstrong (2013)
Levamisole in the treatment of glioblastoma multiforme
S. Fischer (1985)
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.
M. Westphal (2015)
The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
F. Bernard-Arnoux (2016)
International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme.
W. Roa (2015)
Neon heavy charged particle radiotherapy of glioblastoma of the brain.
J. R. Castro (1997)
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme.
P. Sneed (1998)
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
J. Boxerman (2013)
An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment?
M. Chong (2018)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
R. Stupp (2017)
Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis
J. Deeks (2008)
ROBIS: A new tool to assess risk of bias in systematic reviews was developed
P. Whiting (2016)
Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
N. Kontodimopoulos (2009)
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
M. Westphal (2013)
Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus
J. Palmer (2018)
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
L. Bergmann (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
D. Husereau (2013)
[Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas--a cooperative clinical trial].
Y. Ushio (1985)
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
S. Dahlberg (2010)
OS07.2 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial
Hans-Georg Wirsching (2017)
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
J. Clarke (2009)
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
R. Dinapoli (1993)
CCNU‐chemotherapy of hemispheric supratentorial glioblastoma multiforme
F. Cianfriglia (1980)
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
O. Chinot (2016)
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study
K. Hofland (2014)
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
N. Beije (2015)
Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo)
M. Bird (2016)
I. White (2015)
Management of high-grade gliomas in the elderly.
M. Ferguson (2014)
Temozolomide: mechanisms of action, repair and resistance.
J. Zhang (2012)
Treatment of malignant glioma. A controlled study of chemotherapy and irradiation.
W. Shapiro (1976)
Economics of Malignant Gliomas: A Critical Review.
J. Raizer (2015)
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
N. Brown (2016)
Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods
B. O'Brien (2002)
Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients
N. Marshall (2005)
Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery
H. Eyre (2004)
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
M. Westphal (2003)
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
J. Buckner (2006)
Overview of Arterial Thromboembolic Events (ATEs) in AVAglio, a Randomized, Placebo-controlled Phase III Trial of Bevacizumab, Radiotherapy and Temozolomide (BEV+RT/TMZ) for Newly Diagnosed Glioblastoma (S22.003)
W. P. Mason (2014)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
A. Malmström (2012)
Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation
K. Koç (2008)
Biostatistics primer: what a clinician ought to know: hazard ratios.
H. Barraclough (2011)
OP13. GLIOBLASTOMA IN THE OLDER PERSON – HOW DO WE PREDICT THOSE WHO WILL BENEFIT FROM TREATMENT?
C. Lorimer (2017)
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool.
G. Salanti (2012)
Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma.
M. Färkkilä (1994)
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment
F. Pessina (2018)
Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma
Nicolai Skovbjerg Arildsen (2017)
Faut-il irradier les glioblastomes chez les patients âgés ?
S. López (2008)
Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma
W. Shapiro (1989)
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
A. Brandes (2016)
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
ACTR-06. DOSE DENSE TEMOZOLOMIDE (TMZ) AS INITIAL TREATMENT FOR HIGH-RISK OLIGODENDROGLIAL TUMORS: LONG-TERM RESULTS OF A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY
R. Soffietti (2017)
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
W. Wick (2009)
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
M. J. van den Bent (2009)
Debulking or biopsy of malignant glioma in elderly people – a randomised study
V. Vuorinen (2003)
Radiotherapy for glioblastoma in the elderly.
F. Keime-Guibert (2007)
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
J. Gallego Pérez-Larraya (2011)
Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial
Y. Mao (2015)
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study BrUOG 244
H. Elinzano (2018)
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
L. Souhami (2004)
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
M. Taphoorn (2005)
A phase III study of radiation therapy plus carmustine with or without recombinant interferon‐α in the treatment of patients with newly diagnosed high‐grade glioma
J. Buckner (2001)
Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients
S. Kim (2012)
Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
M. Westphal (2005)
Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas
W. Stummer (2017)
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database
D. Blumenthal (2018)
Challenges to Treating Older Glioblastoma Patients: the Influence of Clinical and Tumour Characteristics on Survival Outcomes.
C. Lorimer (2017)
Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial
D. G. Payne (1982)
Cost‐effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme
L. Lamers (2008)
Natural language processing (NLP) of Internet conversations to evaluate prostate cancer (PC) patients' perceptions of active surveillance (AS).
Michele Bennett (2012)
Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data.
L. Mckenzie (2009)
Advances in Brain Tumor Surgery for Glioblastoma in Adults
Montserrat Lara-Velazquez (2017)
ESTRO-ACROP guideline "target delineation of glioblastomas".
M. Niyazi (2016)
Approaches to interpreting and choosing the best treatments in network meta-analyses
L. Mbuagbaw (2017)
Glioblastoma in England: 2007-2011.
A. Brodbelt (2015)
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial
I. Kim (2010)
Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe.
D. Lenartz (2000)
Phase II study of dianhydrogalactitol in malignant glioma.
P. España (1978)
Prospective study evaluating the radiosensitizing effect of reduced doses of temozolomide in the treatment of Egyptian patients with glioblastoma multiforme
M. Gaber (2013)
Effects of valganciclovir as an add‐on therapy in patients with cytomegalovirus‐positive glioblastoma: A randomized, double‐blind, hypothesis‐generating study
G. Stragliotto (2013)
A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001
D. Blumenthal (2014)
[Analysis of the results of combined treatment of poorly differentiated brain gliomas].
J. Peşzyński (1988)
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
H. Athanassiou (2005)
A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.
N. Bleehen (1991)
MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.
W. Wick (2012)
Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for Glioblastoma
M. Kocher (2008)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
W. Wick (2016)
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
W. Stummer (2006)
Checking consistency in mixed treatment comparison meta-analysis.
S. Dias (2010)
Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A
Emile M. Hiesiger (2005)
How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3)
B. Wijnen (2016)
Optimal management of elderly patients with glioblastoma.
N. Laperriere (2013)
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
M. Deutsch (1989)
Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
J. Perry (2017)
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
P. Wen (2010)
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
U. Bogdahn (2011)
Biological response of cancer cells to radiation treatment
R. Baskar (2014)
This paper is referenced by
Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice
W. Shi (2020)
AEBP1 Promotes Glioblastoma Progression and Activates the Classical NF-κB Pathway
Kai Guo (2020)
For older adults with newly diagnosed glioblastoma, how do treatments compare?
Jane Burch (2020)
Chemotherapy toxicities and geriatric syndromes in older patients with malignant gliomas.
Andrea Wasilewski (2020)